Elizabeth Mily Takes the Helm of T1D Fund to Drive Innovations in Type 1 Diabetes Cures Through Impact Investing
On January 8, 2025, the T1D Fund, a pioneering impact investment fund focused on Type 1 Diabetes (T1D), announced the appointment of Elizabeth Mily as its new Chief Executive Officer. With over three decades of experience in the pharmaceutical and healthcare investment sectors, Mily is expected to lead the Fund towards a future filled with innovative treatments and potential cures for T1D.
Elizabeth Mily comes to the T1D Fund after serving as the Executive Vice President of Strategy and Business Development at Bristol Myers Squibb. Her extensive background includes vital leadership roles at major organizations like Goldman Sachs, Barclays, and Thermo Fisher Scientific. This career trajectory has equipped her with a nuanced understanding of corporate strategies, financial markets, and partnership development. Her appointment is viewed as a strategic move to not only enhance the Fund's investment approaches but also to catalyze partnerships that will support the development of advanced therapies targeted at T1D.
"Elizabeth brings a bold strategic vision to the T1D Fund during an exciting period of our evolution," commented Tim Clark, Chair of the Board of Directors at the T1D Fund. This sentiment underscores the organization’s intention to leverage her experience in the healthcare sector to expand its operational capacity and impact.
Under Mily's leadership, the T1D Fund plans to deepen its engagement with venture capital, large biopharma companies, and other foundations to innovate treatment modalities that can potentially transform the lives of those affected by T1D. Mily’s commitment to the mission resonates personally, as she acknowledges the profound effects of this disease, motivating her to spearhead initiatives that aim at creating meaningful changes.
The T1D Fund, established in December 2016, focuses on catalyzing advancements in T1D therapies through a comprehensive financial strategy that incorporates equity investments from various stakeholders. The organization aims to serve as an influential partner in the biopharma sector, enabling breakthroughs to reach the market faster. Mily's role will encompass promoting awareness about T1D, driving investment in research, and fostering innovation aimed at curing the disease.
While discussing the unique position of the T1D Fund as an impact investor, Mily stated, "Our role allows us to not only deploy capital but also work hands-on with biopharma companies to advance innovative therapies that could lead to transformative cures for Type 1 Diabetes." Her strategic approach is expected to galvanize support towards existing and emerging therapies, ultimately aiming at advancing comprehensive solutions for T1D.
Moreover, observers within the industry note that Mily's extensive experience will be significant in fostering a collaborative ecosystem that facilitates faster development of T1D interventions. David Panzirer, a trustee at The Leona M. and Harry B. Helmsley Charitable Trust, highlighted that the T1D Fund's engagement with critical stakeholders like Helmsley and Breakthrough T1D positions it perfectly to address the pressing need for effective treatments for individuals living with the condition.
Moving forward, Elizabeth Mily’s leadership is anticipated to enhance the T1D Fund’s profile, increasing visibility around its mission to develop cutting-edge therapies. Her reputation as a skilled dealmaker will certainly contribute to the Fund's ability to explore unique opportunities and direct attention towards the urgent need for advancements in Type 1 Diabetes care. As she steps into her role, Mily is determined to expand the reach and effectiveness of the T1D Fund, guiding it toward significant breakthroughs that can improve the quality of life for those battling this chronic illness.
In essence, Elizabeth Mily’s appointment as CEO of the T1D Fund marks a critical juncture in the Fund's evolution, setting the stage for impactful collaborations and innovations that could redefine the landscape of Type 1 Diabetes treatment.
Elizabeth Mily comes to the T1D Fund after serving as the Executive Vice President of Strategy and Business Development at Bristol Myers Squibb. Her extensive background includes vital leadership roles at major organizations like Goldman Sachs, Barclays, and Thermo Fisher Scientific. This career trajectory has equipped her with a nuanced understanding of corporate strategies, financial markets, and partnership development. Her appointment is viewed as a strategic move to not only enhance the Fund's investment approaches but also to catalyze partnerships that will support the development of advanced therapies targeted at T1D.
"Elizabeth brings a bold strategic vision to the T1D Fund during an exciting period of our evolution," commented Tim Clark, Chair of the Board of Directors at the T1D Fund. This sentiment underscores the organization’s intention to leverage her experience in the healthcare sector to expand its operational capacity and impact.
Under Mily's leadership, the T1D Fund plans to deepen its engagement with venture capital, large biopharma companies, and other foundations to innovate treatment modalities that can potentially transform the lives of those affected by T1D. Mily’s commitment to the mission resonates personally, as she acknowledges the profound effects of this disease, motivating her to spearhead initiatives that aim at creating meaningful changes.
The T1D Fund, established in December 2016, focuses on catalyzing advancements in T1D therapies through a comprehensive financial strategy that incorporates equity investments from various stakeholders. The organization aims to serve as an influential partner in the biopharma sector, enabling breakthroughs to reach the market faster. Mily's role will encompass promoting awareness about T1D, driving investment in research, and fostering innovation aimed at curing the disease.
While discussing the unique position of the T1D Fund as an impact investor, Mily stated, "Our role allows us to not only deploy capital but also work hands-on with biopharma companies to advance innovative therapies that could lead to transformative cures for Type 1 Diabetes." Her strategic approach is expected to galvanize support towards existing and emerging therapies, ultimately aiming at advancing comprehensive solutions for T1D.
Moreover, observers within the industry note that Mily's extensive experience will be significant in fostering a collaborative ecosystem that facilitates faster development of T1D interventions. David Panzirer, a trustee at The Leona M. and Harry B. Helmsley Charitable Trust, highlighted that the T1D Fund's engagement with critical stakeholders like Helmsley and Breakthrough T1D positions it perfectly to address the pressing need for effective treatments for individuals living with the condition.
Moving forward, Elizabeth Mily’s leadership is anticipated to enhance the T1D Fund’s profile, increasing visibility around its mission to develop cutting-edge therapies. Her reputation as a skilled dealmaker will certainly contribute to the Fund's ability to explore unique opportunities and direct attention towards the urgent need for advancements in Type 1 Diabetes care. As she steps into her role, Mily is determined to expand the reach and effectiveness of the T1D Fund, guiding it toward significant breakthroughs that can improve the quality of life for those battling this chronic illness.
In essence, Elizabeth Mily’s appointment as CEO of the T1D Fund marks a critical juncture in the Fund's evolution, setting the stage for impactful collaborations and innovations that could redefine the landscape of Type 1 Diabetes treatment.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.